Adaptive Immunotherapy for Nasopharyngeal Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adaptive Immunotherapy for Nasopharyngeal Carcinoma — Stella

Recruiting

Back to Nasopharyngeal Cancinoma (NPC) trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Key details

Phase

Large-scale testing

Sponsor

Sun Yat-sen University

Enrollment target

~802 participants

Started

November 2025

Primary completion

September 2031

Age range

18 Years – 65 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov